These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6083576)

  • 1. Hydromorphone effects on human conversational speech.
    Stitzer ML; McCaul ME; Bigleow GE; Liebson IA
    Psychopharmacology (Berl); 1984; 84(3):402-4. PubMed ID: 6083576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
    Preston KL; Bigelow GE; Bickel W; Liebson IA
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1002-9. PubMed ID: 2447262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE; Bigelow GE; Preston KL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous hydromorphone: effects in opiate-free and methadone maintenance subjects.
    McCaul ME; Stitzer ML; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1983 Apr; 43():238-44. PubMed ID: 6192340
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
    Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Apr; 261(1):62-71. PubMed ID: 1373189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc tannate salts of heroin, LAAM and hydromorphone attenuate opiate withdrawal syndrome.
    Brands B; Baskerville JC; Hirst M; Gowdey CW
    Psychopharmacology (Berl); 1980; 68(3):311-4. PubMed ID: 6156472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-choice discrimination in methadone maintenance patients: hydromorphone, naloxone, and saline.
    Preston KL; Bigelow GE; Stitzer ML; Liebson IA
    NIDA Res Monogr; 1984; 55():151-7. PubMed ID: 6085768
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers.
    Hill JL; Zacny JP
    Psychopharmacology (Berl); 2000 Sep; 152(1):31-9. PubMed ID: 11041313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humans.
    Rush CR
    Alcohol Clin Exp Res; 2001 Jan; 25(1):9-17. PubMed ID: 11198720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of morphine, methadone, hydromorphone or oxymorphone on the thermal threshold, following intravenous or buccal administration to cats.
    Pypendop BH; Shilo-Benjamini Y; Ilkiw JE
    Vet Anaesth Analg; 2016 Nov; 43(6):635-642. PubMed ID: 27723230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 2000 Oct; 295(1):114-24. PubMed ID: 10991968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users.
    Levy-Cooperman N; Schoedel KA; Reiz JL; Thompson D; Chakaraborty B; Geoffroy P; Michalko KJ
    J Opioid Manag; 2016; 12(3):165-80. PubMed ID: 27435437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
    Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure.
    Oliveto AH; Bickel WK; Kamien JB; Hughes JR; Higgins ST
    Psychopharmacology (Berl); 1994 Apr; 114(3):417-23. PubMed ID: 7531852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.